StockTipsArenaBeta

BUY Granules India — Emkay Global

BUYGranules India
Granules India share price target & all analyst calls

byEmkay GlobalHorizon: NA (inferred 1 year)22 Jul 2026via Moneycontrol Broker Research

Entry₹853.8Inferred
Target₹950
Total upside +11.27%
Stop lossNot given
CMP₹794.752d ago
Active-6.92%+19.53%upside left 9 mo left
Follow Emkay Global for new calls(64% target hit, 377 closed calls)Get alertsWatch GRANULES for new buy/sell callsGet alertsSee 5 other Long-term calls on GRANULES

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 12:41 am IST
20 supporting11 neutral6 opposing
Supports the BUY call (20)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·23 Oct · 2d ago

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·22 Oct · 3d ago

4 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·15 Oct · 1w ago

Granules India Eyes 180-Day Exclusivity on Generic Ruxolitinib

NewsGoogle News·8 Oct · 2w ago

(opens in new tab)

Granules India has submitted a Paragraph IV certification for its ANDA for Ruxolitinib Extended-Release Tablets, potentially qualifying for first-to-file status and 180 days of generic exclusivity.

NSE · Press Release·7 Oct · 3w ago

(opens in new tab)
Neutral / worth noting (11)

Q2 FY27 results scheduled — board meets 02 Nov 2026

BSE · Board Meeting·In 7 days

(opens in new tab)

Granules India Gagillapur FDA Inspection and Manufacturing Compliance Explained

NewsGoogle News·19 Oct · 6d ago

(opens in new tab)
Weighs against the BUY call (6)

Granules India Faces US FDA Inspection At Gagillapur Facility

NewsGoogle News·19 Oct · 6d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Granules India

All analyst calls on Granules India

More from Emkay Global

Every call and its outcome